Evidence map›Paper›PMID 30622675›Full record

ArticleOxidative medicine and cellular longevity2018

Ewa Skała, Ewelina Synowiec, Tomasz Kowalczyk, Tomasz Śliwiński, Przemysław Sitarek

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oxidative medicine and cellular longevity, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.6field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 16 citations in OpenAlex.

  1. Frontiers in pharmacology · 2026
    Review
  2. Article
  3. Roles of MT-ND1 in Cancer.Current medical science · 2023
    Review
  4. Review
  5. Review
  6. Frontiers in pharmacology · 2022
    Article
  7. Diterpenoids fromPharmaceuticals (Basel, Switzerland) · 2020
    Article
  8. Article
  9. A Network Pharmacology-Based Study on the Anti-Lung Cancer Effect of Dipsaci Radix.Evidence-based complementary and alternative medicine : eCAM · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Ewa SkałaDepartment of Biology and Pharmaceutical Botany, Medical University of Lodz, Muszynskiego 1, 90-151 Lodz, Poland.ORCID 0000-0003-1139-6840
Ewelina SynowiecLaboratory of Medical Genetics, Faculty of Biology and Environmental Protection, University of Lodz, Pomorska 141/143, 90-236 Lodz, Poland.ORCID 0000-0002-0730-4491
Tomasz KowalczykDepartment of Genetics, Plant Molecular Biology and Biotechnology, University of Lodz, Banacha 12/16, 90-237 Lodz, Poland.
Tomasz ŚliwińskiLaboratory of Medical Genetics, Faculty of Biology and Environmental Protection, University of Lodz, Pomorska 141/143, 90-236 Lodz, Poland.
Przemysław SitarekDepartment of Biology and Pharmaceutical Botany, Medical University of Lodz, Muszynskiego 1, 90-151 Lodz, Poland.ORCID 0000-0001-5495-3550
University of Łódź · PLMedical University of Lodz · PL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Adenocarcinoma of LungCell Line, TumorHumansLeukemiaLeuzeaPlant ExtractsPlant RootsPlant Extracts

Identifiers

PMID30622675
PMCPMC6304841
OpenAlexW2904350473

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.